Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
MYLAN PHARMACEUTICALS INC. v. TEVA PHARMACEUTICALS INDUSTRIES LTD. et al
Case Number:
2:21-cv-13087
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
March 03, 2025
Teva Should Face Key Copaxone Antitrust Claims, Court Told
Mylan and pharmaceutical wholesalers should be allowed to proceed with some, but not all, parallel claims accusing Teva of using regulatory deception, false advertising, improper rebates and more to delay generic competition to its Copaxone multiple sclerosis treatment, a special master has recommended in New Jersey federal court.
-
November 22, 2021
Teva Says Mylan Is Just Unhappy About MS Drug Competition
Teva Pharmaceuticals has urged a New Jersey federal court to toss a suit from Mylan accusing the generic-drug giant of an illegal scheme to stifle competition to its multiple sclerosis treatment, arguing that Mylan is just misplacing blame for its own disappointment.